Interactions Between Lipoproteins and Glycosaminoglycans

  • A. L. Catapano
  • E. Trezzi
  • R. Fumagalli
Conference paper
Part of the NATO Advanced Study Institutes Series book series (NSSA, volume 51)


Heparin and other glycosaminoglycans (GAG) are widely distributed in animal species and humans and may play a relevant role in a number of physiological processes. Heparin and GAG, when intravenously injected, induce a deep, transient modification of the blood clotting system, as well as of the plasma lipids disposition. The effect on the coagulation system is mainly due to the interaction of Heparin with antithrombin III, while that on plasma lipoproteins is usually related to the release of lipoprotein lipases from their binding sites. Plasma lipoproteins, however, interact in vivo and in vitro with GAG and Heparin (1). We shall briefly discuss here the lipoprotein-GAG interactions as a relevant phenomenon in the lipoprotein catabolism as well as a tool in the separation of lipoprotein subclasses.


High Density Lipoprotein Unbind Fraction Lecithin Cholesterol Acyl Transferase Lipoprotein Subclass Blood Clotting System 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    G.C. Ghiselli and A.L. Catapano, Glycosaminoglycans and lipoprotein metabolism: an overview, Pharmaco1. Res. Comm. 11: 571 (1979).Google Scholar
  2. 2.
    P.H. Iverius, The interaction between human plasma lipoproteins and connective tissue glycosaminoglycans, J. Biol. Chem. 247: 2607 (1972).PubMedGoogle Scholar
  3. 3.
    Y. Nakashima, N. Di Ferrante, R.L. Jackson, and H.J. Pownall The interaction of human plasma glycosaminoglycans with plasma lipoproteins, J. Biol. Chem. 250: 5386 (1975).PubMedGoogle Scholar
  4. 4.
    M. Bihari-Varga, M. Sztatisz, and S. Gal, Changes in the physical behavior of low density lipoproteins in the presence of glycosaminoglycans and high density lipoproteins, Atherosclerosis 39: 19 (1981).PubMedCrossRefGoogle Scholar
  5. 5.
    M. Simionescu, Structural and functional differentiation of microvascular endothelium in Blood cells and vessel walls, Ciba Foundation Symposium 71, Elsevier, Amsterdam, pp. 39 (1980).Google Scholar
  6. 6.
    C.M. Floren and D. Nilsson, Binding interiorizatio and degradation of cholesteryl ester labelled chylomicrons remnants particles by rat hepatocyte monolayers, Bioch. J. 168: 483 (1977).Google Scholar
  7. 7.
    G.C. Ghiselli, R. Angelucci, A. Regazzoni, and C.R. Sirtori, Metabolism of HDL2 and HDL3 cholesterol by monolayers of rat hepatocytes, FEBS Letters 125: 60 (1981).PubMedCrossRefGoogle Scholar
  8. 8.
    F.A. Shelburne and S.M. Quartford, The interaction of heparin with and apoprotein of human very low density lipoproteins, J. Clin. Invest. 60: 944 (1977).PubMedCrossRefGoogle Scholar
  9. 9.
    K.M. Weisgraber and R.W. Mahley, Subfractionation of human high density lipoproteins by heparin sepharose affinity chromatography, J. Lipid Res. 21: 316 (1980).PubMedGoogle Scholar
  10. 10.
    Y.L. Marcel, C. Vezina, D. Emond, and S. Ginzaburo, Heterogeneity of human high density lipoproteins: presence of lipoproteins with and without apo E and their roles as substrates for lecithin cholesterol acyltransferase reation, Proc. Natl. Acad. Sci. USA 77: 2964 (1980).CrossRefGoogle Scholar
  11. 11.
    L.A. Fransson and B.G. Johansson, Glycosaminoglycan-Lipoprotein interactions: 1. Effect of Uronic acid composition and charge density of the glycan, Int. J. Biol. Macromol. 3: 25 (1981).CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1982

Authors and Affiliations

  • A. L. Catapano
    • 1
  • E. Trezzi
    • 1
  • R. Fumagalli
    • 1
  1. 1.Institute of Pharmacology and PharmacognosyUniversity of MilanMilanItaly

Personalised recommendations